Antares Pharma (ATRS) Stock Rating Lowered by BidaskClub

Share on StockTwits

Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a report issued on Friday.

A number of other brokerages have also issued reports on ATRS. ValuEngine raised Antares Pharma from a “hold” rating to a “buy” rating in a research report on Thursday, July 5th. HC Wainwright set a $4.00 target price on Antares Pharma and gave the stock a “buy” rating in a research report on Wednesday, August 8th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating and set a $4.00 target price on shares of Antares Pharma in a research report on Friday, August 17th.

Shares of Antares Pharma stock opened at $3.21 on Friday. The firm has a market cap of $516.39 million, a PE ratio of -29.18 and a beta of 0.34. The company has a current ratio of 2.33, a quick ratio of 1.89 and a debt-to-equity ratio of 1.01. Antares Pharma has a 12-month low of $1.58 and a 12-month high of $4.09.

Antares Pharma (NASDAQ:ATRS) last announced its earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The company had revenue of $14.16 million for the quarter, compared to analyst estimates of $13.70 million. Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. equities research analysts predict that Antares Pharma will post -0.1 EPS for the current fiscal year.

In related news, CEO Robert F. Apple sold 43,000 shares of the company’s stock in a transaction on Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total transaction of $161,250.00. Following the transaction, the chief executive officer now directly owns 1,573,562 shares of the company’s stock, valued at $5,900,857.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jacques Gonella sold 49,507 shares of the company’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $3.09, for a total value of $152,976.63. Following the transaction, the director now directly owns 9,985,848 shares in the company, valued at $30,856,270.32. The disclosure for this sale can be found here. Insiders have sold 343,000 shares of company stock worth $1,088,250 over the last three months. 12.20% of the stock is owned by insiders.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. raised its position in Antares Pharma by 7.3% during the second quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after buying an additional 664,681 shares during the period. FMR LLC grew its stake in Antares Pharma by 38.8% in the second quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after purchasing an additional 1,018,300 shares in the last quarter. Mycio Wealth Partners LLC purchased a new position in Antares Pharma in the second quarter valued at about $6,278,000. Wells Fargo & Company MN grew its stake in Antares Pharma by 21.5% in the first quarter. Wells Fargo & Company MN now owns 1,933,469 shares of the specialty pharmaceutical company’s stock valued at $4,253,000 after purchasing an additional 342,062 shares in the last quarter. Finally, JW Asset Management LLC grew its stake in Antares Pharma by 2.8% in the second quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock valued at $4,697,000 after purchasing an additional 50,000 shares in the last quarter. 38.93% of the stock is currently owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Antares Pharma  Stock Rating Lowered by BidaskClub
Antares Pharma Stock Rating Lowered by BidaskClub
Reviewing Enterprise Bancorp  & First Community Bancshares
Reviewing Enterprise Bancorp & First Community Bancshares
Head-To-Head Review: CASI Pharmaceuticals  & Cellular Biomedicine Group
Head-To-Head Review: CASI Pharmaceuticals & Cellular Biomedicine Group
Donaldson  Sets New 52-Week High Following Analyst Upgrade
Donaldson Sets New 52-Week High Following Analyst Upgrade
UBS Group Analysts Give Safran  a €125.00 Price Target
UBS Group Analysts Give Safran a €125.00 Price Target
Short Interest in iShares US Preferred Stock ETF  Increases By 97.7%
Short Interest in iShares US Preferred Stock ETF Increases By 97.7%


Leave a Reply

© 2006-2018 Ticker Report. Google+.